GeneDx raises $5M from Blackstone as shares jump 14.8%
What's the deal? GeneDx has raised roughly $5 million through a private placement at $61.00 per share, with participation from a Blackstone affiliate. The genetic testing company's shares rose 14.8% following the announcement, which landed alongside its second-quarter 2026 results.
The numbers: GeneDx reported revenue of $114.44 million for the quarter but a net loss of $17.74 million — a business growing its top line while absorbing wider losses. It reaffirmed full-year 2026 revenue guidance of $475 million to $490 million.
What's the endgame? GeneDx runs a genetic testing franchise and builds data assets it hopes can eventually support profitable growth. The company says the fresh capital will back test volume, payer coverage, and AI platform initiatives.
What could go wrong? The raise modestly strengthens the balance sheet, but funding growth through new equity dilutes existing shareholders. The most cautious analysts assume no profitability within three years, citing reimbursement and regulatory pressures.
Why now? The company disclosed the placement the same week it presented at Canaccord GenuityDealroom has a profile for this one. Try Dealroom →'s 46th Annual Growth Conference in Boston — part of a push for broader investor engagement.
The signal: A small check from a large investor buys GeneDx time. With revenue climbing but losses persisting, the market is watching whether volume and reimbursement momentum can close the gap before more capital is needed.
Read more: Simply Wall St
Image credit: Generated with Gemini
